ATE353363T1 - Immunstimulierende zusammensetzung und verfahren - Google Patents

Immunstimulierende zusammensetzung und verfahren

Info

Publication number
ATE353363T1
ATE353363T1 AT96944879T AT96944879T ATE353363T1 AT E353363 T1 ATE353363 T1 AT E353363T1 AT 96944879 T AT96944879 T AT 96944879T AT 96944879 T AT96944879 T AT 96944879T AT E353363 T1 ATE353363 T1 AT E353363T1
Authority
AT
Austria
Prior art keywords
polypeptide
immuno
disclosed
therapeutic compositions
stimulating composition
Prior art date
Application number
AT96944879T
Other languages
English (en)
Inventor
Reiner Laus
Curtis Landon Ruegg
Hongyu Wu
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Application granted granted Critical
Publication of ATE353363T1 publication Critical patent/ATE353363T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96944879T 1995-12-28 1996-12-23 Immunstimulierende zusammensetzung und verfahren ATE353363T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/579,823 US6080409A (en) 1995-12-28 1995-12-28 Immunostimulatory method

Publications (1)

Publication Number Publication Date
ATE353363T1 true ATE353363T1 (de) 2007-02-15

Family

ID=24318489

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944879T ATE353363T1 (de) 1995-12-28 1996-12-23 Immunstimulierende zusammensetzung und verfahren

Country Status (12)

Country Link
US (3) US6080409A (de)
EP (1) EP0870022B1 (de)
JP (1) JP3908277B2 (de)
AT (1) ATE353363T1 (de)
AU (1) AU716783B2 (de)
CA (1) CA2241373C (de)
DE (1) DE69636891T2 (de)
DK (1) DK0870022T3 (de)
ES (1) ES2281087T3 (de)
NZ (2) NZ326092A (de)
PT (1) PT870022E (de)
WO (1) WO1997024438A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
ES2309992T3 (es) * 1995-10-20 2008-12-16 University Of Nebraska Board Of Regents Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno.
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
EP0972054B1 (de) * 1997-03-27 2008-12-10 Csl Limited Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
US6642013B1 (en) * 1997-08-21 2003-11-04 The University Of Arkansas For Medical Sciences Extracellular serine protease
US7157084B2 (en) * 1997-08-21 2007-01-02 The Board Of Trustees Of The University Of Arkansas System Extracellular serine protease
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
EP1037927B1 (de) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
EP1068296B1 (de) 1998-03-31 2011-08-10 Geron Corporation Zusammensetzungen zur auslösung einer immunantwort gegen ein telomerase antigen
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
CA2328076C (en) * 1998-04-15 2009-10-06 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
EP1104456A1 (de) * 1998-08-10 2001-06-06 Chiron Corporation Genmanipulierte antigenpräsentierende zellen die eine antigengruppe präsentieren, und deren verwendungen
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
DE69839970D1 (de) * 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
EP1261366A4 (de) 2000-02-24 2003-06-18 Univ Leland Stanford Junior Adjuvant-behandlung durch in vivo aktivierung dendritischer zellen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1268763A2 (de) 2000-03-28 2003-01-02 University Of Rochester Verfahren zur herstellung einer bibliothek und zur selektion von polynukleotiden
DK1272633T3 (da) 2000-03-30 2011-05-23 Dendreon Corp Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi
JP5007409B2 (ja) * 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション 樹状細胞に対するヒトモノクローナル抗体
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
CN1330664C (zh) * 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
WO2002087627A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
MXPA04005266A (es) * 2001-12-04 2004-10-11 Merck Patent Gmbh Inmunocitocinas con selectividad modulada.
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
WO2003087338A2 (en) * 2002-04-11 2003-10-23 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7763251B2 (en) * 2002-04-12 2010-07-27 Medical College Of Georgia Research Institute, Inc. Kits to assess the risk of tumor progression
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
WO2003106616A2 (en) * 2002-06-12 2003-12-24 Gavish-Galilee Bio Applications Ltd MEMBRANE-ANCHORED β2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
US20040048258A1 (en) * 2002-09-10 2004-03-11 Windber Research Institute Multiple-gene diagnostic probes and assay kits and method for the assessment of multiple markers for breast cancer prognosis
US7465448B2 (en) * 2002-09-11 2008-12-16 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
NZ539448A (en) * 2002-09-20 2008-03-28 Dendreon Corp Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated prostrate cancers
US7179797B2 (en) * 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
US7169904B2 (en) * 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US20040142328A1 (en) * 2003-01-06 2004-07-22 Windber Research Institute Method and cloning vector for preparing multiple-gene diagnostic probes for the assessment of multiple markers for breast cancer prognosis
ZA200506202B (en) * 2003-01-31 2006-10-25 Celldex Therapeutics Inc Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
EP1601684B1 (de) 2003-03-05 2014-10-15 Dendreon Corporation Zusammensetzungen und verfahren unter anwendung von polypeptiden mit alternativem leserahmen zur behandlung von krebs und infektionskrankheiten
DK1641819T3 (da) 2003-06-25 2009-08-03 Bn Immunotherapeutics Inc Oprensning af HER-2-varianter
CN101094864A (zh) 2003-06-25 2007-12-26 法麦克萨有限公司 Her－2变体的纯化
US20050201992A1 (en) * 2004-03-15 2005-09-15 Moviglia Gustavo A. Tumor/B-cell hybrid cells and uses thereof
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
US8668905B2 (en) * 2005-05-12 2014-03-11 University Of South Florida P53 vaccines for the treatment of cancers
KR100647847B1 (ko) * 2005-05-27 2006-11-23 크레아젠 주식회사 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1951281B1 (de) * 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla klasse ii-bindungspeptide und diese umfassende zusammensetzungen und verfahren
JP2009524420A (ja) * 2006-01-25 2009-07-02 ヴィロ ファルマソイティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ウイルス感染ペプチド（ｓｅｖｉ）のヒト精子増強剤およびその使用
US8361479B2 (en) * 2006-08-11 2013-01-29 Dendreon Corporation Promiscuous PAP CD4 T cell epitopes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2079830B1 (de) 2006-10-04 2016-08-17 Janssen Pharmaceutica NV Herstellung von zellen mit deaktivierten künstlichen antigenen und ihre verwendung in zelltherapien
EP2139498B1 (de) * 2007-03-22 2015-03-18 Dendreon Corporation Verfahren zum nachweis einer natürlichen killer (nk) zell-vermittelten immunantwort und einer erhöhung der nk-zellaktivität
EP2570137A3 (de) * 2007-11-07 2013-08-21 Celldex Therapeutics, Inc. Antikörper zur Bindung von humaner dendritischer und Epithelzelle 205 (DEC-205)
US8666674B2 (en) * 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells
CN104220085A (zh) * 2012-02-16 2014-12-17 渡部昌实 包含融合蛋白的癌症治疗用药物组合物
WO2014087217A1 (en) 2012-12-03 2014-06-12 Subhadra Dravida Allogenic mesendritic vector for ovarian cancer
EP3045180A4 (de) 2013-09-13 2017-06-28 Fundación Pública Andaluza Progreso Y Salud Kombinationen aus aggregationsproteinen und molekularen chaperon-proteinen zur behandlung von proteinopathien oder konformationellen erkrankungen
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
KR20180022949A (ko) * 2015-06-30 2018-03-06 노쓰웨스트 바이오써라퓨틱스, 인크. 향상되거나 증가된 항-종양 면역 반응을 유도하는 최적으로 활성화된 수지상 세포
US20170107580A1 (en) 2015-10-15 2017-04-20 Dendreon Pharmaceuticals, Inc. Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
EP3173098A1 (de) 2015-11-27 2017-05-31 Assistance Publique-Hopitaux De Paris Immunstimulierende zusammensetzungen
US10130658B2 (en) 2015-12-18 2018-11-20 Provectus Pharmatech, Inc. Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
CN105647970A (zh) * 2016-02-22 2016-06-08 河北利同康生物科技有限公司 前列腺癌特异性pap-gm-csf-il-6基因重组融合蛋白及其制备方法
CN110079539B (zh) * 2018-01-25 2022-07-01 上海惠盾因泰生物科技有限公司 前列腺酸性磷酸酶/粒-巨噬细胞集落刺激因子制备方法
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
AU2019333181A1 (en) * 2018-08-31 2021-03-18 The Research Institute At Nationwide Children's Hospital Chimeric oncolytic herpesvirus that stimulate an antitumor immune response
US20220088183A1 (en) * 2018-08-31 2022-03-24 The Research Institute At Nationwide Children's Hospital Chimeric oncolytic herpesvirus that stimulates an antitumor immune response
CN110358735B (zh) * 2019-06-24 2021-09-21 广州安捷生物医学技术有限公司 一种ctl细胞的制备方法及应用
EP3868401A1 (de) 2020-02-21 2021-08-25 Assistance Publique Hôpitaux de Paris Optimierung der peptid-melanin-bindung.
US11761020B2 (en) 2020-10-15 2023-09-19 Aavocyte, Inc. Recombinant adeno-associated virus vectors with CD14 promoter and use thereof
EP4382121A1 (de) 2022-12-07 2024-06-12 Altevax Impfstoffe gegen ptprz1-positive tumore

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
GB8722741D0 (en) * 1987-09-28 1987-11-04 Hoffmann La Roche Induction of cytotoxic t cell response
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE69019609T2 (de) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
DK0633929T3 (da) * 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
AU6363094A (en) * 1993-03-15 1994-10-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptide coated dendritic cells as immunogens
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
AU710783B2 (en) * 1994-06-14 1999-09-30 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo T cell activation by antigen-pulsed dendritic cells
NZ289721A (en) * 1994-07-07 1997-11-24 Immunex Corp Fusion proteins comprising gm-csf and antigens; their expression on yeast
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
AU5801896A (en) * 1995-05-23 1996-12-11 Scripps Research Institute, The Antigen-specific activation of unprimed cd8+ t cells

Also Published As

Publication number Publication date
JP3908277B2 (ja) 2007-04-25
EP0870022B1 (de) 2007-02-07
AU1338097A (en) 1997-07-28
CA2241373A1 (en) 1997-07-10
JP2000502567A (ja) 2000-03-07
NZ500665A (en) 2005-06-24
US6210662B1 (en) 2001-04-03
AU716783B2 (en) 2000-03-09
EP0870022A1 (de) 1998-10-14
NZ326092A (en) 1999-11-29
ES2281087T3 (es) 2007-09-16
PT870022E (pt) 2007-04-30
WO1997024438A1 (en) 1997-07-10
DE69636891D1 (de) 2007-03-22
DE69636891T2 (de) 2007-12-06
CA2241373C (en) 2013-04-09
US6080409A (en) 2000-06-27
US5976546A (en) 1999-11-02
DK0870022T3 (da) 2007-05-21

Similar Documents

Publication Publication Date Title
ATE353363T1 (de) Immunstimulierende zusammensetzung und verfahren
AU2210899A (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
GEP20012519B (en) Method for Controlling Sialylation of Proteins Produced by Mammalian Cell Culture
ES2113088T3 (es) Metodo de entrega de agentes a celulas diana.
NZ288883A (en) Conjugates comprising coagulation factors
MX9602879A (es) Moleculas mutantes de ctla4 y usos de las mismas.
GR3021474T3 (en) Method of delivering molecules into eukaryotic cells
EP1724282A3 (de) Verfahren zur Herstellung von nicht-immunogenen Proteinen
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
EP0986372A4 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
HK1019856A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
AU2741897A (en) Suppression of immune response via inhibition of cathepsin s
DE69637571D1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
DE60144516D1 (de) Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
PT948319E (pt) Celulas encapsuladas produtoras de anticorpos
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
DE69529229D1 (de) Verfahren und testsätze mit makrophagen stimulierenden proteinen
DE69426303D1 (de) Verfahren zur unterdrückung der immunantwort durch gentherapie
Frank et al. Immunobiology of brain tumors
HK1042726A1 (zh) 人類泡沫細胞及其製法，對泡沫細胞的單克隆抗體及其藥效和診斷用途
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.
MX9705082A (es) Composiciones para el suministro de antigenos.
MX9709446A (es) Metodo para preparar un anticuerpo monoclonal, anticuerpo monoclonal, una composicion farmaceutica y un reactivo de diagnostico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0870022

Country of ref document: EP